Skip to main content
. 2022 Jul 27;12(3):2333–2344. doi: 10.1002/cam4.5056

FIGURE 3.

FIGURE 3

(A) Progression‐free survival of the patients with pyrotinib combined with capecitabine (n = 70) and pyrotinib combined with vinorelbine (n = 28); (B) Progression‐free survival of HR‐/HER2‐positive patients with pyrotinib combined with chemotherapy (n = 81) and pyrotinib combined with endorinotherapy (n = 14).